Femasys Inc. reported a net income of $846,100 for the first quarter of 2026, a significant turnaround from a net loss of $5,896,839 in the same period of the previous year. This improvement is attributed to a 24.5% increase in sales, which rose to $424,889 from $341,264, primarily driven by the sales of its FemVue product. The company's operating expenses decreased by 21% to $4,489,816, down from $5,684,605, reflecting a substantial reduction in research and development costs, which fell by 55.9% to $1,309,401.
In terms of financial position, Femasys reported total assets of $16,495,245 as of March 31, 2026, down from $20,724,177 at the end of 2025. The decrease in total assets was accompanied by a reduction in total liabilities, which fell to $9,205,352 from $14,854,875. The company’s cash and cash equivalents also decreased to $5,386,041 from $9,266,353, indicating a need for additional financing to support ongoing operations and product development.
Strategically, Femasys has made significant advancements in its product offerings and market presence. The company announced the commercial launch of FemaSeed Complete, a comprehensive fertility solution, and initiated patient enrollment in the pivotal clinical trial for its FemBloc permanent birth control system. Additionally, Femasys has formed strategic partnerships to enhance the distribution of its products in various international markets, including Switzerland and Israel.
Operationally, Femasys has seen a notable increase in customer engagement, with a focus on expanding its market share in women's health solutions. The company has also made organizational changes, including the appointment of John Canning as Chief Operating Officer to drive operational execution and support commercial growth. As of March 31, 2026, Femasys had approximately 60.4 million shares outstanding, reflecting ongoing efforts to manage its equity structure effectively.
Looking ahead, Femasys anticipates continued investment in its commercialization efforts and product development, particularly for FemBloc and FemaSeed. However, the company acknowledges the need for additional financing to sustain operations beyond the third quarter of 2026. Management has expressed concerns regarding liquidity and the ability to secure necessary funds, which could impact future growth and operational stability.
About FEMASYS INC
Femasys Inc. develops women’s health solutions, including non-surgical permanent birth control, artificial insemination, and diagnostic devices. Its products serve infertility and contraception markets worldwide, offering minimally invasive, cost-effective alternatives to surgery and traditional treatments. With a strong patent portfolio and regulatory approvals, the company focuses on innovative, in-office medical devices that improve safety, accessibility, and patient satisfaction in reproductive health.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.